



Slade, E., Keeney, E., Mavranouzouli, I., Dias, S., Fou, L., Stockton, S., Saxon, L., Waller, G., Turner, H., Serpell, L., Fairburn, C. G., & Kendall, T. (2018). Treatments for bulimia nervosa: a network meta-analysis. *Psychological Medicine*, 1-8.
<https://doi.org/10.1017/S0033291718001071>

Peer reviewed version

Link to published version (if available):
[10.1017/S0033291718001071](https://doi.org/10.1017/S0033291718001071)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Cambridge Core at <https://www.cambridge.org/core/journals/psychological-medicine/article/treatments-for-bulimia-nervosa-a-network-metaanalysis/E2F5EDDEF98F480DED2FB09AF87C12F8>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Treatments for bulimia nervosa: a network meta-analysis

First and last name	Institutional affiliations	Email address
Eric Slade, MSc	National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, London, NW1 4RG, UK	eslade@rcog.org.uk T: +44 20 7045 6750
Edna Keeney, MSc	University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS	edna.keeney@bristol.ac.uk
Ifigeneia Mavranouzouli, PhD	Research Department of Clinical, Educational & Health Psychology, University College London 1-19 Torrington Place, London, WC1E 7HB National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, London, NW1 4RG, UK	i.mavranouzouli@ucl.ac.uk
Sofia Dias, PhD	University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS	s.dias@bristol.ac.uk
Linyun Fou, PhD	National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, London, NW1 4RG, UK	lfou@rcog.org.uk
Sarah Stockton, BA Hons	National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, London, NW1 4RG, UK	sstockton@rcog.org.uk

Leanne Saxon, PhD	<p>Research Department of Clinical, Educational & Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB</p> <p>National Guideline Alliance, Royal College of Obstetricians and Gynaecologists; 27 Sussex Place, London, NW1 4RG, UK</p>	lsaxon@rcog.org.uk ; l.saxon@ucl.ac.uk
Glenn Waller, DPhil	<p>Department of Psychology, University of Sheffield, Floor D, Cathedral Court, 1 Vicar Lane, Sheffield, S1 2LT</p>	g.waller@sheffield.ac.uk
Hannah Turner, PhD	<p>Southern Health NHS Foundation Trust, April House, 9 Bath Road, Bitterne, Southampton, SO19 5ES</p>	hannahturner0@googlemail.com
Lucy Serpell, PhD	<p>University College London, 1-19 Torrington Place, London, WC1E 7HB</p> <p>Eating Disorder Service, North East London Foundation NHS Trust, Porters Avenue Health Centre, 234 Porters Avenue, Dagenham, Essex RM8 2EQ</p>	l.serpell@ucl.ac.uk
Christopher G Fairburn, MD	<p>University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX</p>	credo@medsci.ox.ac.uk
Tim Kendall, MRCPsych	<p>National Collaborating Centre for Mental Health, Royal College Of Psychiatrists, 21 Prescott St, Whitechapel, London E1 8BB</p>	tim.kendall1@nhs.net

5

6

7 **ABSTRACT**

8 **Background.** Bulimia nervosa is a severe eating disorder that can be managed using a
9 variety of treatments including pharmacological, psychological, and combination treatments.
10 We aimed to compare their effectiveness and to identify the most effective for the treatment
11 of bulimia nervosa in adults.

12 **Methods.** A search was conducted in Embase, Medline, PsycINFO and Central from their
13 inception to July 2016. Studies were included if they reported on treatments for adults who
14 fulfilled diagnostic criteria for bulimia nervosa. Only RCTs that examined available
15 psychological, pharmacological, or combination therapies licensed in the UK were included.
16 We conducted a network meta-analysis (NMA) of RCTs. The outcome analysed was full
17 remission at the end of treatment.

18 **Results.** We identified 21 eligible trials with 1,828 participants involving 12 treatments,
19 including wait list. The results of the NMA suggested that individual CBT (specific to eating
20 disorders) was most effective in achieving remission at the end of treatment compared with
21 wait list (OR 3.89, 95% CrI 1.19 to 14.02), followed by guided cognitive behavioural self-help
22 (OR 3.81, 95% CrI 1.51 to 10.90). Inconsistency checks did not identify any significant
23 inconsistency between the direct and indirect evidence.

24 **Conclusions.** The analysis suggested that the treatments that are most likely to achieve full
25 remission are individual CBT (specific to eating disorders) and guided cognitive behavioural
26 self-help, although no firm conclusions could be drawn due to the limited evidence base.
27 There is a need for further research on the maintenance of treatment effects and the
28 mediators of treatment outcome.

29 **Key words:** eating disorder, bulimia nervosa, network meta-analysis, outcome research,
30 National Institute of Health and Care Excellence.

31 **Word count:** 248 (abstract); 3,745 (main paper)

INTRODUCTION

Bulimia nervosa (BN) is an eating disorder with an estimated lifetime prevalence of 1-3% (Trace et al. 2012; Smink et al. 2013; Stice et al. 2013). It is characterised by recurrent binge eating, extreme weight-control behaviour and an overconcern about body shape and weight (Cooper and Fairburn, 1993; Fairburn and Harrison, 2003) and generally starts in late adolescence or early adulthood. Although it usually begins with strict dieting and some weight loss, this dietary restriction becomes punctuated after some months or years by repeated binges and weight regain. In most cases, people with BN engage in purging and compensatory behaviours that include the use of excessive exercise and/or dietary restriction.

Cognitive behavioural therapy specific to eating disorders (CBT-ED) has been demonstrated to be an effective approach for the treatment of BN (Hay, 2013; Poulsen et al. 2014; Fairburn et al. 2015; Linardon et al. 2017). Some evidence suggests that interpersonal psychotherapy (IPT) can achieve results similar to CBT, although it is much slower to achieve these effects (Fairburn et al. 1993; Agras et al. 2000). The more recent 'enhanced' form of CBT appears to be more effective than IPT even at follow-up (Fairburn et al. 2015). There is also evidence that supports the use of guided cognitive behavioural self-help (Bailer et al. 2004; Wagner et al. 2013). There are many more treatments for BN, although data on their outcomes are limited to date.

Traditional pairwise meta-analyses of RCTs are used to synthesize the results of different trials comparing the same pair of treatments, to obtain an overall estimate of the effect of one treatment relative to another. However, the few extant meta-analyses of treatments for people with BN have been limited to comparisons of a narrow range of treatments (Whittal et al. 2000; Thompson-Brenner et al. 2003; Hay, 2013; Polnay et al. 2014; Linardon et al. 2017). Network meta-analysis (NMA) has advantages over standard pairwise meta-analysis in that (1) all the treatments that have been tested in RCTs can be simultaneously compared to each other in one analysis; and (2) their effects can be estimated relative to each other

and to a common reference condition (such as a wait list). Estimates of the relative effects of pairs of treatments that have often, rarely, or never been directly compared in an RCT can be calculated. Consequently, an NMA overcomes some of the limitations of a traditional meta-analysis in which conclusions are largely restricted to comparisons between treatments that have been directly compared in RCTs (Dias et al. 2013).

An NMA was developed and conducted of all psychological, pharmacological, and combination therapies that are used for the treatment of adult BN, and which have been tested in RCTs. This NMA was used to inform the new national clinical guidance for eating disorders in England released by the National Institute for Health and Care Excellence (NICE, 2017). The guideline was developed by a Guideline Committee, an independent multi-disciplinary team consisting of clinical academics, health professionals and service users and carer representatives with expertise and experience in the field of eating disorders. This article reports the findings of the NMA that was conducted to inform the NICE guideline on the most effective treatments for BN in adults.

METHODS

Search strategy

A search for published and unpublished studies on the treatment of adults with eating disorders was conducted in the databases Embase, Medline, PsycINFO and Central to inform the NICE guideline. All databases were searched from their inception to July 2016 and no language limits were set. The strategy used terms covering all eating disorders, in accordance with the NICE guideline scope. The balance between sensitivity (the power to identify all studies on a particular topic) and specificity (the ability to exclude irrelevant studies from the results) was carefully considered, and a decision was made to utilise a broad, population-based approach to the search in order to maximise retrieval in a wide range of areas. To aid retrieval of relevant and sound studies, 'filters' were used (where appropriate) to limit the search results to RCTs. See Supplementary Appendix 1 for full details of the search terms used.

Selection criteria

A systematic review of interventions for BN was carried out according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009).

The titles and abstracts of identified studies were screened by two reviewers against inclusion criteria specified in the guideline review protocols, until a good inter-rater reliability was observed (percentage agreement $\geq 90\%$, or Kappa statistic $K > 0.60$) (NICE, 2017). Any disagreements between raters were resolved through discussion. Once full versions of the selected studies were acquired for assessment, full studies were checked independently by two reviewers, with any differences being resolved with discussion. Data were extracted on the study characteristics, aspects of the methodological quality, outcome data, and risk of bias.

RCTs for the systematic review of treatments for BN were included if they reported on treatments for people aged at least 18 years who fulfilled diagnostic criteria for BN (i.e. DSM-

IV). Two reviewers independently assessed eligibility: studies were included if they were RCTs examining psychological, pharmacological, or combination therapies compared with a wait list, pill placebo, or another active treatment. Nutritional management was not considered in the review as this was seen as an add on to treatments for people with BN. Also, only treatments available and licensed in the UK for BN were included.

According to the NICE Guideline Committee's expert view, it was important to differentiate between CBT-specific to eating disorders (CBT-ED) and generic CBT. CBT-ED is the leading form of treatment for BN that places emphasis on the eating disorder psychopathology and may have some differences in efficacy when compared with CBT non-specific to eating disorders. It was also considered important to distinguish between group and individual treatments, and between pure and guided cognitive behavioural self-help because there may be some differences in efficacy and also on cost effectiveness, which is an important factor when making recommendations for NICE guidelines.

Network meta-analysis

To take all trial information into consideration, network meta-analytic techniques (mixed treatment comparisons) were employed to synthesise evidence. The critical outcomes in the systematic review conducted for the NICE guideline were remission, long-term recovery, and binge eating. The guideline systematic review of the clinical literature identified only one dichotomous outcome that could be utilised in the NMA - full remission at the end of treatment – as the reporting of the other outcome measures was inconsistent across the trials. The NMA was also used to inform a cost-effectiveness analysis and the Guideline Committee was of the view that full remission at the end of treatment was an important outcome to pursue in the economic evaluation.

The identified RCTs employed a range of definitions of full remission, utilising criteria such as abstinence from binge eating and purging. Following consultation with the NICE Guideline Committee, RCTs were included only if they defined full remission as either the abstinence

of bulimia-related symptoms over a minimum of a two week period, or as no longer meeting DSM-IV criteria for BN (including cognitive elements). The definition of remission was decided before selection of studies. A number of excluded studies employed shorter time frames or lesser symptom reduction. However, stricter criteria for defining full remission were used because the fluctuating nature of symptom severity and gaps between behaviours in BN mean that a shorter time period would not be clinically meaningful. In studies where the time frame for remission was unclear, the Guideline Committee was consulted to decide whether the study should be included in the review.

A network of treatments included in the systematic review, for which data on full remission at end of treatment were available, was designed. Only treatments that were connected to the network were considered. Treatment-as-usual arms were excluded, since the definitions of 'treatment-as-usual' varied across the studies and were therefore not informative to the Guideline Committee. Head-to-head comparisons of no interest (such as interventions not available or licensed for BN in the UK, as well as controls of no interest) were excluded from the analysis unless they allowed indirect comparisons between interventions of interest (see Supplementary Appendix 2 for details of the included studies in the NMA). An intention to treat (ITT) analysis was adopted when estimating full remission (that is, all randomised patients were included and anyone discontinuing treatment, for whatever reason, was assumed not to be in remission). The flowchart diagram for the NMA is provided in Figure 1.

Insert Figure 1

The Committee made an *a priori* assumption that there would need to be at least 200 people randomised to a treatment across all included trials in the NMA for them to make a recommendation with confidence.

Statistical analysis

Both fixed effects and random effects models (Binomial Likelihood and Logit link) were run (see the Supplementary Appendix 3 and 4 for WinBUGS fixed effects and random effects

model codes, respectively) (Dias et al. 2011A). The goodness-of-fit of each model to the data was measured by comparing the posterior mean of the summed deviance contributions to the number of data points (Dempster, 1997). The Deviance Information Criterion (DIC), which is equal to the sum of the posterior mean of the residual deviance and the effective number of parameters, was used as the basis for model comparison (Spiegelhalter et al. 2002). Model selection was also influenced by the posterior mean between study heterogeneity standard deviation (SD). Analyses were undertaken in a Bayesian framework, using WinBUGS 4.1.3 (Lunn et al. 2013).

Relative effects are reported as odds ratios with 95% credible intervals (CrI). Treatments were also ranked based on their effectiveness, with lower ranks indicating more effective treatments. Median ranks and 95% CrI are presented for each treatment.

Continuity correction

In the dataset, several studies reported zero events of interest in some arms (that is, the number of people achieving full remission was zero). Combining such data can be problematic: when zero events occur in some arms of a study, the log-odds ratio becomes undefined (as does the variance), which causes problems in the analysis and precludes the estimation of relative effects. As a result, continuity corrections are needed. Using a continuity correction for studies with zero counts allows the log-odds ratio to be estimated, and hence allows synthesis via standard NMA methods. There are many possible continuity correction methods (Sweeting et al. 2004). In the present study, a continuity correction of 0.5 was added to both the number of events and the number of non-events across all study arms, in studies in which one or more (but not all) arms had zero events.

Inconsistency checks

A basic assumption of an NMA is that direct and indirect evidence estimate the same parameter. That is, the relative effect between A and B measured directly from an A versus B trial is the same as the relative effect between A and B estimated indirectly from A versus C and B versus C trials. Inconsistency arises when there is a conflict between direct

179 evidence (from an A versus B trial) and indirect evidence (gained from A versus C and B
180 versus C trials). This consistency assumption has also been termed the similarity or
181 transitivity assumption (Mavridis et al. 2015).

182 Evidence of inconsistency was checked for by comparing the standard network consistency
183 model to an 'inconsistency', or unrelated mean effects, model (Dias et al. 2013). The latter is
184 equivalent to having separate, unrelated meta-analyses for every pair-wise contrast but with
185 a common variance parameter in random effects models. Improvement in model fit or a
186 substantial reduction in heterogeneity in the inconsistency model compared to the NMA
187 consistency model, indicates evidence of inconsistency. The WinBUGS code for the
188 inconsistency model is provided in the Supplementary Appendix 5 (Dias et al. 2011B).

RESULTS

Identified studies and treatments

Seventy-five potentially eligible studies were identified, 54 of which were excluded (Figure 1). Twenty-one trials with 1,828 participants provided direct or indirect evidence on full remission associated with 12 treatment options: wait list, individual CBT-ED, individual interpersonal psychotherapy (IPT), guided cognitive behavioural self-help, individual behaviour therapy (BT), pure cognitive behavioural self-help (i.e., self-help with no support), group CBT-ED group, fluoxetine, relaxation, individual CBT-ED plus fluoxetine, group BT, and supportive psychotherapy. Among the 21 trials there were 6 studies ($N = 452$) comparing the same treatment in both arms (e.g. CBT-ED vs. CBT-ED, etc.). Nevertheless, these were retained in the NMA as they contributed to the estimation of between-study heterogeneity. The resulting network of trials contributing data to the NMA is presented in Figure 2. (Full details of the excluded studies are provided in the Supplementary Appendix 6 and the final data file used in the NMA is shown in Supplementary Appendix 7.)

Insert Figure 2

Risk of bias assessment

All included trials were assessed for risk of bias using the GRADE risk of bias tool (Balshem et al. 2011; Guyatt et al. 2011). Sequence generation and allocation concealment were adequately described in eleven and three trials, respectively. Trials were regarded at high risk of bias for lack of participant and provider masking. In four studies, assessors were aware of treatment assignment, and in four trials it was unclear if the assessors were blinded. Attrition was high in most trials. However, we used ITT analysis and treated drop outs as failures. As a result, attrition bias was not considered in the assessment. Included trials reported a variety of outcomes. Only two trials were registered on a trials database. Consequently, most studies were judged as being at unclear risk of reporting bias. No other

potential biases were identified. (Risk of bias tables are presented in the Supplementary Appendix 8.)

NMA model fit statistics

Convergence was satisfactory after at least 70,000 iterations. Models were then run for a further 70,000 iterations on two separate chains, and results are based on this further sample. The fixed and random effects models had a similar fit to the data when comparing the posterior mean residual deviance and DIC values. Moderate to high between-trials heterogeneity was observed when a random effects model was used ($\tau=0.43$, 95% CrI 0.04 to 0.93), which was of a similar magnitude to the relative effects expressed on the log-odds ratio scale (see Supplementary Appendix 9). No substantial differences were observed in posterior mean residual deviance or DIC values compared to the inconsistency model, which suggests no inconsistency. Model fit statistics for the fixed and random-effects models, continuity corrected, and for the random-effects inconsistency model are provided in Supplementary Appendix 10. The random effects model had a slightly more favourable fit than the fixed effects, therefore all further analyses are based on that model.

Treatment outcomes

The posterior median odds ratios (OR) and 95% CrI for each treatment for achieving full remission at the end of treatment compared to every other treatment are reported in Table 1. Compared with wait list, individual CBT-ED (OR 3.89, 95% CrI 1.19 to 14.02), guided cognitive behavioural self-help (OR 3.81, 95% CrI 1.51 to 10.90), pure cognitive behavioural self-help (OR 3.49, 95% CrI 1.20 to 11.21), group CBT-ED (OR 7.67, 95% CrI 1.51 to 55.66), and group BT (OR 28.70, 95% CrI 3.11 to 455.3) were significantly better at achieving full remission at the end of treatment. Group BT was also better than IPT, fluoxetine, individual BT, and relaxation. However, as indicated by the very wide 95% CrI, there was high uncertainty regarding the treatment effects of group BT and group CBT-ED. These therapies had very small numbers randomised across all studies and, as a result, their effects were very uncertain. Although there were differences in the mean effects

between any other treatments, these were not statistically significant. The posterior median log odds ratios (LOR) and 95% CrI for each treatment compared to every other for achieving full remission at the end of treatment as estimated by the NMA (and, where available, the respective results from the pairwise analysis) are provided in Supplementary Appendix 9. The NMA and pairwise results were in agreement in all cases, which strengthens the results of the NMA.

Figure 3 shows the ORs (on a log-scale) in remission compared to wait list. Most of the treatments had very wide CrI and crossed the line of no effect. Most CrI also overlapped, indicating no difference between the treatments.

Insert Table 1

Insert Figure 3

Treatment rankings

The treatments with the lowest posterior median rank were group BT (1st, 95% CrI 1st to 5th), followed by group CBT-ED (3rd, 95% CrI 1st to 9th), individual CBT-ED (4th, 95% CrI 2nd to 7th), and guided cognitive behavioural self-help (5th, 95% CrI 2nd to 8th). Table 2 shows the posterior median ranks and the associated 95% CrI.

Insert Table 2

The full results of the NMA are provided in Supplementary Appendix 11.

DISCUSSION

To our knowledge, this is the first reported NMA in people with BN. Only one previous NMA in people with eating disorders was identified, examining the effectiveness of psychological and pharmacological interventions for binge-eating disorder (Peat et al. 2017). Overall, the results of the present NMA suggest that group BT, group CBT-ED, individual CBT-ED and guided cognitive behavioural self-help are more effective than other treatments in achieving full remission at the end of treatment. The findings for group BT and group CBT-ED were based on very small numbers randomised ($N < 70$), and were characterised by very wide CrI. Similarly, the evidence for other treatments, with the exception of IPT, was limited. However, the mean effects for these treatments suggest a less good outcome when compared with cognitive or behavioural therapies. As a result, individual CBT-ED and guided cognitive behavioural self-help are the treatments for which there is the most reliable evidence. Also, the inconsistency checks did not identify any significant inconsistency between the direct and indirect evidence included in the NMA, which strengthens the conclusions of the analysis.

Not all trials identified in the systematic review provided data on full remission. 'Full remission' was not clearly defined in some RCTs, and there was wide variation in its definition when it was reported. In particular, a number of RCTs were excluded because remission was defined as abstinence from bulimia-related symptoms over a period of less than 2 weeks. According to the NICE Guideline Committee's expert opinion only abstinence from bingeing over and above two weeks should be considered. Although this two-week period was seen as a relatively weak definition, more stringent inclusion criteria would have excluded the majority of studies since only few of them had longer reported periods.

It is acknowledged that not meeting full DSM-IV criteria is not the same as abstinence from binge eating and compensatory behaviours, and it could potentially include people in partial remission. However, given a limited evidence base the committee made a decision to

include such studies. Use of the DSM-V criteria would have been more inclusive but DSM-IV criteria was still in operation when nearly all of the studies were conducted.

It should also be noted that papers used inconsistent definitions of behaviour change. Future research needs to adopt consistent and rigorous definitions. It is proposed that 'abstinence' be defined as (1) no objective binges or purging behaviours over the previous three months and (2) being not underweight. Similarly, 'full remission' should be defined as abstinence, plus attitudes towards eating, weight and shape within one standard deviation of the community range for the relevant population.

The ITT analysis meant that all participants were analysed in the group to which they had been randomized and all study non-completers were assumed to not be in remission. This strategy was supported by the NICE guideline committee and provides a conservative estimate of treatment effects.

It was not possible to investigate whether the end of treatment effects persisted or diminished in the long term because most trials stopped at the end of treatment (usually at 16 weeks). Hence, there was insufficient evidence to inform an NMA using remission data at long-term follow-up. Also, even though we included only those treatments available and licensed for use in the UK, only one trial was excluded on the grounds of being of no interest (Pope et al. 1989, which compared trazodone with pill placebo). The findings should therefore be of interest to an international audience.

One limitation of the study is that the literature search is over a year old. However, a literature search on PubMed (conducted March 2018) failed to identify any relevant new RCTs.

The finding that, among the treatments with a robust evidence base, individual CBT-ED appears to be the most effective option to achieve remission at the end of treatment for people with BN is in line with other systematic reviews (Linardon et al. 2017; Polnay et al. 2014; Hay, 2013; Shapiro et al. 2007). Our analysis suggests that guided cognitive

behavioural self-help is also effective. This outcome is also consistent with the findings of systematic reviews by Beinter et al. (2014) and Linardon et al. (2017), which showed that cognitive behavioural self-help treatments are useful in the treatment of BN (especially if the features of their delivery and indications are considered carefully).

A review by Polnay et al. (2014) suggested that group CBT was effective compared with no treatment. However, there was insufficient evidence in their review on the effectiveness of group CBT relative to individual CBT. Our use of mixed treatment methodology enabled us to compare group therapies with other available treatment options. Although group CBT-ED and group BT were effective in achieving remission at the end of treatment, the estimates of effect were extremely uncertain. Similarly, even though combination therapies (e.g. CBT plus fluoxetine) and other psychological therapies (including individual IPT and individual BT) have shown some efficacy in individual studies, our synthesis pooled evidence using direct and indirect comparisons and found their effects small compared with other available treatments.

The present analysis found no convincing evidence for the effectiveness of pharmacological treatments although few studies provided direct comparisons between psychological therapies and pharmacological treatments.

Taking all these factors into account, the NICE guideline recommended that bulimia-nervosa-focused guided self-help should be offered as the first treatment for adults with BN in a stepped care treatment strategy, with the second step being individual eating-disorder-focused cognitive behavioural therapy (CBT-ED) (NICE, 2017).

Overall the evidence base was limited, in particular for a range of treatments. There is a clear need for well-conducted head-to-head studies that examine the effectiveness of pharmacological, individual as well as group psychological, and combined pharmacological and psychological therapies compared to each other for adults with BN. In particular, long-term comparative outcome data are needed.

CONTRIBUTORS

EK contributed to the NMA analyses, conducted inconsistency checks

ES carried out the NMA and the associated analyses, and wrote the first draft of the manuscript

IM contributed to the study conception, planning, and NMA analyses

LF contributed to carrying out the systematic reviews, data extraction, proof reading and copy editing

LSa contributed to carrying out the systematic reviews, and data extraction

SD contributed to the NMA analyses, and conducted inconsistency checks

ST performed search strategy

TK contributed to the study conception and interpretation of the results

CGF, GW, HT and LSe provided clinical input and interpretation of the results and their clinical implications

All authors contributed to the write up of the manuscript and approved the final version for submission.

ACKNOWLEDGMENTS

We thank the Guideline Committee for the NICE guideline on ‘Eating disorders: recognition and treatment’ (Anthony Bateman, Jane Dalgliesh, Ivan Eisler, Christopher Fairburn, Lee Hudson, Mike Hunter, Dasha Nicholls, Jessica Parker, Daniel Perry, Ursula Philpot, Susan Ringwood, Mandy Scott, Lucy Serpell, Phillip Taylor, Dominique Thompson, Janet Treasure, Hannah Turner, Christine Vize, and Glenn Waller). We also thank Nick Harris and Barry Johnston for editorial input.

FINANCIAL SUPPORT

This work was initiated by the National Collaborating Centre for Mental Health (NCC-MH) and continued by the National Guideline Alliance (NGA) at the Royal College of

Obstetricians and Gynaecologists (RCOG) from 1st April 2016. NCC-MH and NGA received funding from NICE to develop clinical and social care guidelines. The views expressed in this publication are those of the authors and not necessarily those of the RCOG, NGA, NCC-MH or NICE. "National Institute for Health and Care Excellence (2017) Eating disorders: recognition and treatment. Available from <https://www.nice.org.uk/guidance/ng69>".

The funder of the study had no further role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

CONFLICTS OF INTERESTS

ES, IM, LF, LSa, ST, and TK received support from the NGA, which was in receipt of funding from NICE for the submitted work.

SD and EK received support from the NICE Guidelines Technical Support Unit, University of Bristol, with funding from the Centre for Guidelines (NICE). The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

CGF is the author of research papers, review articles and books that have commented on the effectiveness of various treatments for eating disorders (including BN). Royalties received from publishers of the books concerned. CGF held (paid and unpaid) training workshops for clinicians on eating disorders; on eating disorder treatment in general; and on specific treatments for eating disorders (CBT; IPT; guided self-help). CGF is involved in developing an online means of training therapists in a specific treatment for eating disorders, including CBT. CGF is supported by a Principal Fellowship from the Wellcome Trust (046386).

LSr has no declarations of conflict of interest.

HT is teaching and conducting research/publications in CBT. She is also involved in the development and evaluation of brief CBT interventions for eating disorders and in an effectiveness study of CBT when delivered in routine clinical settings.

389 GW published books and a range of papers and book chapters on CBT for eating disorders;
390 regularly gives workshops on evidence-based CBT for eating disorders.

391 **SUPPORTING INFORMATION**

392 Additional Supporting Information may be found in the online version of this article:

393 Appendix 1: Search strategy

394 Appendix 2: Characteristics of the included studies and references

395 Appendix 3: WinBUGS code for the fixed effects model

396 Appendix 4: WinBUGS code for the random effects model

397 Appendix 5: WinBUGS code for the inconsistency model

398 Appendix 6: List of excluded studies

399 Appendix 7: Final data file for the NMA

400 Appendix 8: Risk of bias of included studies

401 Appendix 9: Posterior median log odds ratios and 95% credible intervals for each treatment
402 compared with every other

403 Appendix 10: Model fit statistics for the fixed and random-effects models, continuity
404 corrected, and for the random-effects inconsistency model

405 Appendix 11: Summary statistics of WinBUGS random effects model

REFERENCES

- Agras WS, Walsh T, Faairburn CG, Wilson GT, Kraemer** (2000). A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. *Archives of General Psychiatry* **57**, 459-466.
- Bailer U, De Zwaan M, Leisch F, Strnad, A, Lennkh-Wolfsberg C, El-Giamal N, Hornik K, Kasper S** (2004). Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa. *International Journal of Eating Disorders* **35**, 522-537.
- Balshem H, Helfand M, Schunemann HJ** (2011). GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology* **64**, 401-406.
- Beintner I, Jacobi C, Schmidt UH** (2014). Participation and outcome in manualized self-help for bulimia nervosa and binge eating disorder - a systematic review and metaregression analysis. *Clinical Psychology Review* **34**, 158-76.
- Cooper PJ, Fairburn CG** (1993). Confusion over the core psychopathology of bulimia nervosa. *International Journal of Eating Disorders* **13**, 385-389.
- Dempster A** (1997). The direct use of likelihood for significance testing. *Statistics and Computing* **7**, 247-252.
- Dias S, Welton NJ, Sutton AJ, Ades AE** (2011A). NICE DSU Technical support document 2: a generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials (last updated 2016).
- Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE** (2011B). NICE DSU Technical support document 4: inconsistency in networks of evidence based on randomised controlled trials (last updated 2014).

429 **Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE** (2013). Evidence synthesis
 430 for decision making 4: inconsistency in networks of evidence based on randomized
 431 controlled trials. *Medical Decision Making* **33**, 641-656.

432 **Fairburn CG, Bailey-Straebler S, Basden S, Doll HA, Jones R, Murphy R, O'Connor ME,**
 433 **Cooper Z** (2015). A transdiagnostic comparison of enhanced cognitive behaviour therapy
 434 (CBT-E) and interpersonal psychotherapy in the treatment of eating disorders. *Behaviour*
 435 *Research and Therapy* **70**, 64-71.

436 **Fairburn CG, Harrison PJ** (2003). Eating disorders. *Lancet* **361**, 407-416.

437 **Fairburn CG, Jones R, Peveler RC, Hope RA, O'Connor M** (1993). Psychotherapy and
 438 bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and
 439 cognitive behavior therapy. *Archives of General Psychiatry* **50**, 419-428.

440 **Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,**
 441 **Glasziou P, Debeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ**
 442 (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of
 443 findings tables. *Journal of Clinical Epidemiology* **64**, 383-394.

444 **Hay P** (2013). A systematic review of evidence for psychological treatments in eating
 445 disorders: 2005-2012. *International Journal of Eating Disorders* **46**, 462-469.

446 **Linardon J, Wade TD, de la Piedad Garcia X, Brennan L** (2017). The efficacy of cognitive-
 447 behavioral therapy for eating disorders: A systematic review and meta-analysis. *Journal of*
 448 *Consulting and Clinical Psychology* **85**, 1080-1094.

449 **Lunn D, Jackson C, Best N, Thomas A** (2013). The BUGS book, Boca Raton, Florida,
 450 CRC Press.

451 **Mavrisis D, Giannatsi M, Cipriani A, Salanti G** (2015). A primer on network meta-analysis
 452 with emphasis on mental health. *Evidence Based Mental Health* **18**, 40-46.

453 **Moher D, Liberati A, Tetzlaff J, Altman DG, Group P** (2009). Preferred reporting items for
454 systematic reviews and meta-analyses: the PRISMA statement. *Journal of Clinical*
455 *Epidemiology* **62**, 1006-12.

456 **NICE** (2017). Eating disorders: recognition and treatment. NICE clinical guideline 69.
457 London: National Institute for Health and Care Excellence.

458 **Peat CM, Berkman ND, Lohr KN, Brownley KA, Bann CM, Cullen K, Quattlebaum MJ,**
459 **Bulik CM** (2017). Comparative Effectiveness of Treatments for Binge-Eating Disorder:
460 Systematic Review and Network Meta-Analysis. *European Eating Disorder Review* **25**, 317-
461 328.

462 **Polnay A, James VA, Hodges L, Murray GD, Munro C, Lawrie SM** (2014). Group therapy
463 for people with bulimia nervosa: systematic review and meta-analysis. *Psychological*
464 *Medicine* **44**, 2241-2254.

465 **Poulsen S, Lunn S, Daniel SI, Folke S, Mathiesen BB, Katznelson H, Fairburn CG**
466 (2014). A randomized controlled trial of psychoanalytic psychotherapy or cognitive-
467 behavioral therapy for bulimia nervosa. *American Journal of Psychiatry* **171**, 109-116.

468 **Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM** (2007). Bulimia
469 nervosa treatment: a systematic review of randomized controlled trials. *International Journal*
470 *of Eating Disorders* **40**, 321-336.

471 **Smink FR, Van Hoeken D, Hoek HW** (2013). Epidemiology, course, and outcome of eating
472 disorders. *Current Opinion in Psychiatry* **26**, 543-548.

473 **Spiegelhalter D, Best N, Carlin B, Van Der Linde A** (2002). Bayesian measures of model
474 complexity and fit. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*
475 **64**.

476 **Stice E, Marti CN, Rohde P** (2013). Prevalence, incidence, impairment, and course of the
 477 proposed DSM-5 eating disorder diagnoses in an 8-year prospective community study of
 478 young women. *J Journal of Abnormal Psychology* **122**, 445-457.

479 **Sweeting J, Jackson C, Best N, Thomas A, Spiegelhalter D** (2004). What to add to
 480 nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
 481 *Statistics in Medicine* **23**, 1351-1375.

482 **Thompson-Brenner H, Glass S, Westen D** (2003). A Multidimensional Meta-Analysis of
 483 Psychotherapy for Bulimia Nervosa. *Clinical Psychology: Science and Practice* **10**, 269-287.

484 **Trace SE, Thornton LM, Root TL, Mazzeo SE, Lichtenstein P, Pedersen NL, Bulik CM**
 485 (2012). Effects of reducing the frequency and duration criteria for binge eating on lifetime
 486 prevalence of bulimia nervosa and binge eating disorder: implications for DSM-5.
 487 *International Journal of Eating Disorders* **45**, 531-536.

488 **Wagner G, Penelo E, Wanner C, Gwinner P, Trofaier ML, Imgart H, Waldherr K, Wober-**
 489 **Bingol C, Karwautz AF** (2013). Internet-delivered cognitive-behavioural therapy v.
 490 conventional guided self-help for bulimia nervosa: long-term evaluation of a randomised
 491 controlled trial. *British Journal of Psychiatry* **202**, 135-141.

492 **Whittal ML, Agras WS, Gould RA** (2000). Bulimia nervosa: A meta-analysis of
 493 psychosocial and pharmacological treatments. *Behaviour Therapy* **30**, 117-135.

494

Figure 1. PRISMA flowchart.





Figure 2. Network diagram of studies included in analysis of bulimia nervosa treatments.



Note: The width of the lines is proportional to the number of trials directly comparing each pair of treatments. The size of each node is proportional to the number of randomised participants to each intervention (sample size).

Legend: CrI, Credible Interval; BT, behaviour therapy; CBT-ED, cognitive behavioural therapy specific to eating disorders; IPT, interpersonal psychotherapy

Figure 3




Table 1. Median odds ratios and 95% CrI for every individual treatment compared with every other. (Lower triangle presents the results of the network meta-analysis and the upper triangle the results of available direct pair-wise comparisons)

Supportive psychotherapy	-	-	-	-	-	-	-	-	-	0.68 (0.06; 6.12)	-
0.09 (0.00; 2.64)	Group BT	-	-	-	-	-	-	-	-	-	23.10 (2.22; 601.85)
1.34 (0.09; 18.51)	14.93 (0.90; 350.30)	Individual CBT-ED plus fluoxetine	-	-	-	-	-	-	-	0.51 (0.12; 1.98)	-
2.80 (0.16; 42.63)	31.53 (1.60; 858.40)	2.13 (0.26; 16.90)	Relaxation	0.61 (0.14; 2.15)	-	-	-	-	-	-	-
2.08 (0.14; 24.25)	22.47 (1.46; 505.30)	1.55 (0.26; 8.51)	0.72 (0.23; 2.31)	Individual BT	-	-	-	-	-	0.39 (0.12; 1.36)	-
2.72 (0.17; 40.13)	30.14 (1.75; 781.50)	2.02 (0.44; 9.94)	0.95 (0.12; 9.05)	1.31 (0.22; 8.95)	Fluoxetine	-	-	-	-	0.25 (0.05; 1.06)	-
0.33 (0.01; 6.67)	3.62 (0.59; 33.25)	0.26 (0.02; 2.58)	0.12 (0.01; 1.51)	0.16 (0.01; 1.55)	0.12 (0.01; 1.34)	Group CBT-ED	-	-	4.07 (0.31; 124.71)	-	5.71 (0.76; 79.04)
0.75 (0.05; 9.45)	8.19 (0.71; 144.80)	0.57 (0.09; 3.32)	0.27 (0.04; 1.98)	0.37 (0.07; 1.88)	0.28 (0.04; 1.71)	2.18 (0.35; 18.43)	Pure cognitive behavioural self-help	-	-	-	3.64 (1.20; 13.16)
2.01 (0.16; 20.46)	21.83 (1.66; 435.30)	1.53 (0.30; 6.57)	0.71 (0.13; 3.79)	0.99 (0.28; 3.28)	0.74 (0.13; 3.64)	5.83 (0.75; 56.47)	2.68 (0.63; 10.83)	IPT	-	0.32 (0.15; 0.76)	-
0.68 (0.05; 7.97)	7.46 (0.75; 118.40)	0.52 (0.09; 2.66)	0.24 (0.04; 1.68)	0.33 (0.07; 1.53)	0.26 (0.04; 1.42)	1.98 (0.38; 14.57)	0.91 (0.30; 2.73)	0.34 (0.10; 1.29)	Guided cognitive behavioural self-help	0.93 (0.25; 3.43)	4.38 (1.47; 15.41)
0.68 (0.06; 6.33)	7.38 (0.63; 136.80)	0.51 (0.13; 1.85)	0.24 (0.05; 1.23)	0.33 (0.11; 1.03)	0.25 (0.05; 1.01)	1.95 (0.30; 17.56)	0.89 (0.27; 2.97)	0.33 (0.16; 0.76)	0.98 (0.36; 2.82)	Individual CBT-ED	3.47 (0.52; 24.17)
2.63 (0.17; 35.07)	28.70 (3.11; 455.30)	1.98 (0.33; 12.27)	0.92 (0.13; 7.62)	1.28 (0.25; 7.22)	0.97 (0.14; 6.50)	7.67 (1.51; 55.66)	3.49 (1.20; 11.21)	1.30 (0.33; 6.24)	3.81 (1.51; 10.90)	3.89 (1.19; 14.02)	Wait list

Legend: CrI, Credible Interval; BT, behaviour therapy; CBT-ED, cognitive behavioural therapy specific to eating disorders; IPT, interpersonal psychotherapy.

Table 2. Posterior median rank and 95% CrI. (The lower the rank the better the treatment).

Treatment	Posterior median rank	95% CrI
Group BT	1	1 – 5
Group CBT-ED	3	1 – 9
Individual CBT-ED	4	2 – 7
Guided cognitive behavioural self-help	5	2 – 8
Pure cognitive behavioural self-help	5	2 – 10
Supportive psychotherapy	6	1 – 12
Individual CBT-ED plus fluoxetine	7	2 – 12
Individual BT	9	4 – 12
IPT	9	5 – 12
Fluoxetine	10	4 – 12
Relaxation	10	3 – 12
Wait list	10	6 – 12

Legend: CrI, Credible Interval; BT, behaviour therapy; CBT-ED, cognitive behavioural therapy specific to eating disorders; IPT, interpersonal psychotherapy.